Atrial fibrillation (AF) is the most common cardiac arrhythmia. Chronic kidney disease (CKD) is associated with a high prevalence of AF, and uremic toxins are an important risk factor for cardiovascular diseases associated with CKD. Uremic toxins can produce pro-fibrotic, pro-hypertrophic, and pro-inflammatory effects on cardiac tissues and enhance oxidative stress or neurohormonal phenomena of cardiovascular injury, which are recognized as arrhythmogenic factors of AF. This article reviews the clinical, molecular, and electrophysiological data of uremic toxins in CKD considered to induce AF through multiple mechanisms on structural and electrical remodeling of the cardiovascular system.

**Key Words:** Atrial fibrillation • Inflammation • Oxidative stress • Uremic toxins

**INTRODUCTION**

Atrial fibrillation (AF), the most common clinical arrhythmia, causes significant cardiovascular mortality and morbidity due to heart failure and stroke. AF is produced by enhanced trigger activity from ectopic foci or the genesis of reentry circuits in atrial substrates. Chronic kidney disease (CKD) is associated with a higher prevalence of AF. Uremic cardiomyopathy is a distinctive type of heart failure associated with CKD. Uremic cardiomyopathy can be produced by a reduced microvascular supply, enhanced cardiac fibrosis, progressive inflammation, and oxidative stress. In addition, anemia, hypertension, and activation of the renin-angiotensin-aldosterone and sympathetic nervous systems may contribute to the occurrences of uremic cardiomyopathy in CKD. The pathological effects of CKD are essential arrhythmogenic factors of AF. However, traditional cardiovascular risk factors are insufficient to accurately predict cardiovascular mortality or morbidity with CKD.

A novel risk factor, uremic toxins, was proposed as contributing to the cardiovascular burden with CKD. Uremic toxins cannot be removed by conventional hemodialysis. Uremic toxins, such as indoxyl sulfate (IS), p-cresol (PC), and p-cresol sulfate (PCS), which originate from protein fermentation can increase oxidative stress and inflammation or activate the neurohormonal system which results in cardiovascular fibrosis and oxidative injury. On the other hand, uremic toxins produce pro-fibrotic, pro-hypertrophic, and pro-inflammatory phenomena in cardiomyocytes. In addition, IS was already proved to induce arrhythmogenesis in the pulmonary veins (PVs), sinoatrial node (SAN), and left atrium (LA) through oxidative stress in an animal study.
Accordingly, uremic toxins may contribute to the genesis of AF through direct and indirect effects on structural and electrical remodeling.

**CLINICAL STUDIES OF UREMIC TOXINS IN CARDIOVASCULAR SYSTEM**

Uremic toxins play an important role in the progression of CKD and increase the risk of cardiovascular diseases (CVDs; Table 1). Higher level of IS increased all cause mortality and CV mortality in common or elderly hemodialysis patients, which was demonstrated with vascular disease in patients over 40 years of age. Serum total PCS and free PCS both were recognized as novel risk factor of CV events independent of age, diabetes, anemia, malnutrition, glomerular filtration rate, and calcium-phosphate imbalance in hemodialysis patients. Therefore, these results implied that uremic toxins may increase the potential risk of atrial arrhythmia during the progression of uremic toxins-induced CVDs.

**UREMIC TOXINS ON CARDIAC OXIDATIVE STRESS AND INFLAMMATION**

Oxidative stress is a substantial character in the pathophysiology of AF. Such oxidative stress modulates inflammation, ischemia, heart failure, and renin-angiotensin or adrenergic activation, which are known to increase the occurrence of AF. Oxidative stress produces structural remodeling through enhancing fibrosis, apoptosis, and fatty metamorphosis in the atrium. In addition, oxidative stress can change the atrial and thoracic venous electrophysiology. Fukunaga et al. demonstrated that oxidative stress can enhance AF vulnerability in an animal model of CKD.

Oxidative stress was also demonstrated to shorten the atrial effective refractory period and induce automaticity of the atrium and thoracic veins by increasing calcium release through the opening of ryanodine receptors. Additionally, oxidative stress induces mitochondrial dysfunction in the atrium, which also plays a role in the pathophysiology of atrial arrhythmogenesis. Uremic toxins, such as IS and PCS, can activate leukocytes in the endothelium, which generates an inflammatory reaction through reactive oxygen species (ROS), the nuclear factor-κB pathway, monocyte chemoattractant protein-1, and intercellular adhesion molecule-1 (Table 2). These data suggest that uremic toxins could have direct effects on atrial arrhythmogenicity and proinflammatory effects in CKD. Moreover, recent study has shown that the antioxidant suppressed IS-induced PV brust firing. Additionally, slower beating rate and

<table>
<thead>
<tr>
<th>Table 1. Effects of indoxyl sulfate (IS), p-cresol (PC), and p-cresol sulfate (PCS) on cardiovascular risks</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Author</strong></td>
</tr>
<tr>
<td>--------------------------</td>
</tr>
<tr>
<td>Barreto et al.</td>
</tr>
<tr>
<td>Meijers et al. (2002-2003)</td>
</tr>
<tr>
<td>Meijers et al. (2005-2006)</td>
</tr>
<tr>
<td>Wu et al.</td>
</tr>
</tbody>
</table>

CKD, chronic kidney disease; HR, hazard ratio; GFR, glomerular filtration rate.
shorter action potential (AP) duration of SAN and LA cardiomyocytes, respectively, induced by IS also can be inhibited by the antioxidant. Hence, it demonstrated that IS can change electrical activities of PV, SAN, and LA cardiomyocytes through oxidative stress. Furthermore, oxidative stress can induce a Ca\(^{2+}\)-overload, which interrupts the regulation protein of the calcium channel, and higher expression of the intracellular Ca\(^{2+}\) overload and Ca\(^{2+}\) release may increase the contractility of atrial cardiomyocytes.\(^{24,35}\)

**UREMIC TOXINS ON STRUCTURAL REMODELING IN AF**

Thoracic veins and the left atrium are critical AF triggers (AF initiation) and substrates (AF maintenance).\(^ {36,37}\) Animals with CKD were associated with higher atrial arrhythmogenicity due to structural remodeling with enhanced atrial fibrosis, which can be produced by uremic toxins through their potential for pro-fibrotic and hypertrophic expression with activation of mitogen-activated protein kinase, transforming growth factor-β1, connective tissue growth factor, atrial natriuretic peptide, β-myosin heavy chain, and α-skeletal muscle actin (Table 2).

The dilated LA and thoracic veins are common findings of CKD patients, which could promote the occurrence of AF via structural remodeling with fibrotic molecular expression and mechanoelectrical feedback.\(^ {9,10,38,39}\) Furthermore, uremic toxins such as IS also activate tumor necrosis factor (TNF)-α, interleukin (IL)-6, and IL-1β genes, which can cause cardiac fibrosis and hypertrophy and lead to the genesis of heart failure and atrial arrhythmias.\(^ {19}\) Moreover, IS has been shown to modulate the PV vascular tone via increasing calcium leakage from increased ryanodine receptor open probability.\(^ {22}\) Since mechanical stretch plays a critical role in the arrhythmogenesis of PV, IS may contribute to the occurrence of atrial arrhythmia in CKD.

**UREMIC TOXINS ON ELECTRICAL REMODELING IN AF**

Larger calcium leak in IS-treated PV cardiomyocytes was investigated to have more delayed after depolarizations (DADs) with increased PV beating rate in the rabbit study as shown in Figure 1.\(^ {22}\) IS has been shown to increase calcium leaks in PV cardiomyocytes, which can facilitate the genesis of trigger activity due to diastolic calcium overload and DADs. In addition, IS-induced calcium leak may induce the increased PV diastolic tension shown in this cardiomyocyte study. However, IS did not change the calcium transient and sarcoplasmic reticulum calcium content of PV cardiomyocytes. Hence, ab-

---

**Table 2.** The pathways of uremia toxins related to cardiovascular disease

<table>
<thead>
<tr>
<th>Cytokine/transcription factor/ionic current</th>
<th>Target</th>
<th>Function/effect</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>TNF-α, IL-6, IL-1β, MAPK (p38, p42/44), NF-κB</td>
<td>Cardiac fibroblasts and myocytes in rats</td>
<td>Pro-fibrotic, pro-hypertrophic, and pro-inflammatory effects</td>
<td>[19]</td>
</tr>
<tr>
<td>Inhibit NO production; induce NADPH (Nox4) and superoxide</td>
<td>HUVECs</td>
<td>ROS generation</td>
<td>[33]</td>
</tr>
<tr>
<td>ICAM-1, MCP-1</td>
<td>HUVECs</td>
<td>NF-κB</td>
<td>[34]</td>
</tr>
<tr>
<td>EMPs, calcium</td>
<td>HUVECs in vivo and in vitro - HUVECs</td>
<td>Endothelial damage</td>
<td>[41]</td>
</tr>
<tr>
<td>TGF-β, CTGF, ANP, β-MHC, α-skeletal muscle actin</td>
<td>Cardiac tissues of rats</td>
<td>Fibrosis and hypertrophy</td>
<td>[21]</td>
</tr>
<tr>
<td>PKCα</td>
<td>Cardiac myoblasts of a cell line from rats</td>
<td>Disruption of cardiomyocyte adherent junctions</td>
<td>[20]</td>
</tr>
</tbody>
</table>

ANP, atrial natriuretic peptide; CTGF, connective tissue growth factor; EMPs, endothelin microparticles; HUVECs, human umbilical vein endothelial cells; ICAM-1, intercellular adhesion molecule 1; IL-1β, interleukin-1β; IL-6, interleukin-6; MAPK, mitogen-activated protein kinase; MCP-1, monocyte chemoattractant protein 1; MHC, β-myosin heavy chain; NADPH, nicotinamide adenine dinucleotide phosphate; NF-κB, nuclear factor-kappa B; ROS, reactive oxygen species; TGF-β, transforming growth factor-β; TNF-α, tumor necrosis factor-α; β-PKCα, protein kinase Ca.
normal calcium regulation plays an important role in electrical remodeling of IS-treated PV cardiomyocyte. Moreover, shorter AP duration of IS-treated LA cardiomyocytes had higher occurrence and longer duration of pacing-induced AF in the infusion of isoproterenol, which might indicate micro-reentry circuit with decreasing effective refractory period in the same study.

PC and PCS can disrupt nitric oxide signaling and induce shedding of endothelial microparticles with possibly higher cellular calcium concentration by blockage of the Rho-kinase pathway. Impairment of the endothelial system due to uremic toxins can modulate the arrhythmogenic activity of pulmonary veins through a vasoconstrictor effect and multiple electromechanical mechanisms. Moreover, activation of the renin-angiotensin-aldosterone system plays a critical role in the pathological processes of the AF trigger and substrate. Uremic toxins significantly activate angiotensin II type 1 receptor expression, which might shorten the action potential duration, modulate ionic currents, and disrupt calcium handling to cause AF. Further, uremic toxins increase intracellular calcium levels and activate protein kinase Ca that can damage adherent junctions of cardiomyocytes to increase irregular beats and electrical activity. Accordingly, the electrical effects of uremic toxins can enhance AF trigger arrhythmogenesis due to calcium dysregulation and facilitate AF maintenance with conduction block and shortening of refractoriness.

CONCLUSIONS

Since there is a high incidence of CVDs and AF associated with CKD, researchers are dedicated to finding relationships among traditional and novel cardiovascular risk factors. Subsequently, uremic toxins are being emphasized as new targets for cardiovascular therapy, and even in dialysis patients. The AF trigger and AF substrate are modulated by structural and electrical remodeling to induce atrial arrhythmias with interactions among NADPH-oxidation, ROS, and the renin-angiotensin-aldosterone system (Figure 2). Correspondingly, uremic tox-
ins produce pro-fibrotic, pro-hypertrophic, and pro-inflammatory effects in both renal and cardiovascular cells in response to oxidative stress and calcium handling. The mechano-electrical feedback directly increases trig-ger activity and maintains the reentry of the substrate as a result of atrial arrhythmogenicity. Therefore, the appropriate management of uremic toxins in CKD should attenuate the potential capacity for atrial arrhythmias and achieve better prognoses of CVDs.

CONFLICT OF INTEREST STATEMENT

None declared.

FINANCIAL SUPPORT

This work was supported by the Ministry of Science and Technology, Taiwan, (MOST 103-2314-B-038-041-MY2, MOST 103-2314-B-281-005-MY2, MOST 103-2314-B-038-055), the Cathay General Hospital, Taiwan, (CGH-MR-10221, CGH-MR-10223), and the Taiwan Heart Rhythm Society (THRS-1501).

REFERENCES